Repligen (NASDAQ:RGEN) Releases FY21 Earnings Guidance

Share on StockTwits

Repligen (NASDAQ:RGEN) issued an update on its FY21 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $2.21-2.28 for the period, compared to the Thomson Reuters consensus estimate of $1.91. The company issued revenue guidance of $565-590 million, compared to the consensus revenue estimate of $513.50 million.Repligen also updated its FY 2021 guidance to 2.210-2.280 EPS.

NASDAQ:RGEN traded down $13.44 during trading hours on Tuesday, hitting $194.67. The stock had a trading volume of 572,290 shares, compared to its average volume of 383,206. The company has a market cap of $10.69 billion, a PE ratio of 237.40, a price-to-earnings-growth ratio of 4.18 and a beta of 0.94. The business has a 50 day simple moving average of $204.63 and a two-hundred day simple moving average of $198.93. Repligen has a 1-year low of $109.38 and a 1-year high of $228.84. The company has a current ratio of 13.67, a quick ratio of 12.13 and a debt-to-equity ratio of 0.21.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 4th. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.26. The firm had revenue of $142.80 million for the quarter, compared to the consensus estimate of $117.88 million. Repligen had a net margin of 13.40% and a return on equity of 6.58%. The firm’s quarterly revenue was up 87.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 EPS. Research analysts expect that Repligen will post 1.44 EPS for the current fiscal year.

A number of research firms recently weighed in on RGEN. Craig Hallum increased their price target on Repligen from $245.00 to $251.00 and gave the company a buy rating in a research report on Thursday, February 25th. HC Wainwright reiterated a buy rating and issued a $225.00 price objective (up from $168.00) on shares of Repligen in a research note on Monday, April 19th. Zacks Investment Research downgraded Repligen from a strong-buy rating to a hold rating and set a $200.00 price objective for the company. in a research report on Tuesday, January 5th. Finally, SVB Leerink increased their price objective on shares of Repligen from $220.00 to $250.00 and gave the company an outperform rating in a research note on Wednesday, March 3rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $215.20.

In other news, Director Thomas F. Ryan, Jr. sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 3rd. The stock was sold at an average price of $205.00, for a total value of $205,000.00. Following the transaction, the director now owns 2,464 shares of the company’s stock, valued at $505,120. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Ralf Kuriyel sold 2,075 shares of the stock in a transaction that occurred on Thursday, March 4th. The stock was sold at an average price of $192.00, for a total transaction of $398,400.00. Following the transaction, the vice president now owns 26,940 shares in the company, valued at approximately $5,172,480. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,382 shares of company stock worth $9,056,388. Insiders own 1.70% of the company’s stock.

Repligen Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Article: Certificate of Deposit (CD) For Risk Adverse Investors?

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.